Objective:
High concentrations of antituberculosis (anti-TB) drugs can be associated with many adverse drug reactions (ADRs). The objective of this study was to examine the plasma concentrations of rifampicin (RMP) and isoniazid (INH) in patients with and without ADRs.
Methods:
Concentration monitoring data of patients treated with anti-TB drugs were retrospectively analyzed from 2009 to 2011. RMP and INH plasma concentrations were measured 2 and 3 h after drug administration respectively using high-performance liquid chromatography.
Results:
A total of 54 out of 120 patients have experienced ADRs to anti-TB drugs. The median concentrations [interquartile range (IQR)] obtained in patients with and without ADRs were 6.7 mg/l (3.7–9.9) and 5.6 mg/l (2.9–8.6) (p = 0.56) for RMP and 4.3 mg/l (2.3–5.3) and 3.1 mg/l (1.7–4.8) (p = 0.04) for INH, respectively. Related median doses (IQR) were 8.7 mg/kg (8.0–10.0) and 8.6 mg/kg (6.5–9.9) (p = 0.42) for RMP and 4.8 mg/kg (4.3–5.0) and 4.0 mg/kg (2.8–5) (p < 0.01) for INH, respectively. Concentrations above the expected range in patients with and without ADRs were not reached for RMP, but were 76% and 65% for INH, respectively. Correlation between concentrations and doses has not been established for RMP or INH. In addition, high INH concentrations showed no association with sex, age, liver injury or renal or diabetes.
Conclusions:
High INH concentrations were common in patients with and without ADRs whereas RMP concentrations were low or within the normal range in most patients. Further studies are required to assess the association between high INH concentrations and the occurrence of ADRs.
The objective of this work is to demonstrate the interest of integration of pharmacovigilance in Moroccan Tuberculosis Control Program (MTCP). The integration of pharmacovigilance in MTCP was conducted in October 2012with the Global Fund support. We compared the reports notified before and after this integration (period 1: January 2010–October2012; period 2: October 2012–December 2013). The detection of signals was based on the Information Component available inVigiMine. We used the SPSS version 10.0 and Med Calc version 7.3 for data analysis. The average number of spontaneous reports increased from 3.6 to 37.4 cases/month (P< 10-3). The average age was 40.7 ± 17.5 years; the sex ratio was 0.8. Hepatic reactions (32.7%) predominated during the first period, while skin reactions (24.1%) were in the second period (P = 10-4), and40.9% of cases in the first period were serious against 15.8% in second period (P = 0.003). Nine signals were generated (hepaticenzyme increase, cholestasis, jaundice, arthralgia, acne, lower limb edema, pruritus, skin rashes, and vomiting). The integration of pharmacovigilance in Moroccan Tuberculosis Control Program improved the management of ADRs and detected new signals of antituberculosis drugs.
IntroductionLe suivi thérapeutique pharmacologique (STP) des médicaments antiépileptiques (MAE) est un outil très utilisé dans la gestion de l'épilepsie. Au Maroc, ce dosage est réalisé au Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM) depuis Avril 1995.MéthodesIl s'agit d'une étude rétrospective s'étalant sur 20 ans. Elle concerne le STP du Phénobarbital (PB), de la Carbamazépine (CBZ) et de l'Acide Valproique (AVP).RésultatsLe STP des 3 MAE représentaient 58,85% de l'ensemble des demandes de STP reçue par le CAPM. Le dosage du PB était classé en première position suivi par celui de la CBZ et enfin par l'AVP. La faible demande de STP au Maroc pouvait être expliquée par le faible nombre de neurologues auquel s'ajoutaient des facteurs sociaux. Grâce à son prix très accessible par les patients, le PB est le MAE le plus prescrit dans notre pays expliquant ainsi la demande élevée de son dosage. Quant aux motifs de STP des 3 MAE, ils étaient essentiellement liés à l'âge, à l'apparition d'effets indésirables, à l'association de MAE ou dans le cas de vérification de l'observance des malades.ConclusionDes efforts sont à fournir pour promouvoir l'intérêt du STP des MAE dans la prise en charge de l'épilepsie au Maroc.
Tuberculosis is a world public health problem. Its treatment is based on a set of drugs that can cause many side effects. Liver toxicity remains one of the most common and severe side effect causing treatment failure. The objective of this study is to demonstrate the interest of therapeutic drug monitoring in the treatment of tuberculosis through the experience of the Laboratory of Toxicology and Pharmacology of the Anti Poison Center. This retrospective study involved 1152 patients who had benefited from a determination of plasma levels of first line antitubureculosis drugs (isoniasid, pyrazinamid, rifampicin) during 15 years. 135 patients had developed hepatotoxicity. The study showed that at therapeutic dose, 71.2% of TB patients had plasma concentrations lower than the therapeutic range, and 57.8% of patients had isoniazid plasma concentrations above the therapeutic range. This interindividual variability justifies the need for therapeutic drug monitoring to assess an inadequate response to tuberculosis treatment and prevent the development of hepatotoxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.